Verona Pharma
plc
("Verona Pharma" or the
"Company")
2015 in review – A
successful year with significant progress
21 March 2016, Cardiff –
Verona Pharma plc (AIM: VRP.L), the drug development company
focused on first-in-class medicines to treat respiratory diseases,
today provides a summary review of its 2015 performance.
Primary goals in 2015 were centred around initiating and
completing a series of clinical trials on its drug candidate,
RPL554, using the Company’s new proprietary nebulised suspension
formulation. RPL554 is a novel inhaled PDE3/PDE4 inhibitor with
both bronchodilator and anti-inflammatory properties, currently in
development as a nebulised treatment for acute exacerbations in
chronic obstructive pulmonary disease (COPD) patients in a hospital
or home-care setting.
Commenting on progress, CEO Jan-Anders
Karlsson said:
“At the time of our 2014 fund raise we laid out our plans for
further development of RPL554, initially to address severe COPD.
Based on the strength of the emerging clinical data, we
decided in early 2015 to accelerate this development plan.
“To date almost 300 subjects have
been included in clinical trials with RPL554. Collectively these
data consistently highlight that the drug is an effective
bronchodilator and has a broad anti-inflammatory profile.
Importantly, it is well-tolerated over a wide dose range and
adverse events are similar to those in subjects treated with
placebo.
“Having made marked clinical progress with RPL554, we are
currently considering all options for further funding of our
development programmes. As part of this process, and as previously
stated, the Company recognises that the right commercial partner
could bring significant value to the development of RPL554 for
chronic maintenance treatment in COPD and perhaps asthma.
Verona Pharma therefore continues to be involved in business
development discussions around the RPL554 programme.“
2015 Highlights
-
Initiation and successful completion of a Single Ascending Dose
(SAD) and Multiple Ascending Dose (MAD) Phase I/II trial in 112
healthy volunteers and COPD patients using the new suspension
formulation of RPL554
-
Initiation and successful completion of a dose-finding Phase IIa
study in 29 patients with chronic persistent asthma in comparison
to salbutamol and placebo1
-
Initiation and end of clinical stage of Phase IIa study in 30
COPD patients in which RPL554 was administered on top of standard
of care bronchodilators; results expected in Q2 2016
-
Board of Directors strengthened by appointment of Dr
Anders Ullman and Dr Ken Cunningham, two physicians highly
experienced in the development of respiratory medicines
-
Loss before tax expected at approximately £8.9m for the year
ended 31 December 2015 (2014:£2.8m),
broadly in line with market expectations, reflecting tight cost
control despite the planned increase in R&D spend, especially
on clinical studies
-
Cash balance (unaudited) at 31 December
2015 was GBP 3.5 million
(2014: £10.0); Clinical activity is expected to be at a lower level
in 2016 than in 2015 as the Company plans the next tranche of
clinical studies. Thus the Board believes the Company has
sufficient capital to progress RPL554 to the start of Phase IIb
clinical trials, earmarked to begin around the end of 2016.
Marked Clinical Progress with
RPL554
During 2015 the Company made excellent progress in developing
the new proprietary nebulised suspension formulation of RPL554. The
clinical studies which completed in 2015, the results of which have
since been reported, exposed this new formulation to healthy
volunteers, and to COPD and asthma patients. Results
consistently showed that the product has a pharmacokinetic profile
which permits twice-daily dosing, and that it elicits a profound
dose dependant bronchodilator response. There was also an absence
of serious adverse events. Additionally, the clinical segment of a
Phase II study examining nebulised RPL554 as an add-on treatment to
standard bronchodilators such as ipratropium and salbutamol was
also completed during 2015 and we expect top line data to be
available in Q2 2016. Three presentations of some of the results of
these studies will be made at the American Thoracic Society meeting
in San Francisco in mid
May 2016.
The Company is highly encouraged by the results demonstrated
with this new formulation of RPL554 and is preparing plans to
progress this formulation into a Phase IIb clinical programme to
investigate treatment of acute exacerbations in COPD. The nebuliser
bronchodilator market was estimated to be worth about $1 billion in 2014 in the US.2
The Company is also planning additional pre-clinical and
clinical work in Cystic Fibrosis and potentially other respiratory
conditions.
Board of Directors Further
Strengthened During the Year
The Company also significantly strengthened the Board of
Directors during the year. Dr Anders
Ullman, who joined the Board in September 2015, was previously Chief Medical
Officer at Nycomed (now Takeda) and was responsible for the
development and approval of roflumilast (Daxas®) which was
approved for the treatment of COPD. He also oversaw the initiation
of a post-approval Phase IV study (the REACT study) which was
published in the Lancet in February
2015. This study demonstrated that treatment with the PDE4
Inhibitor roflumilast leads to a 24% reduction in severe COPD
exacerbations even in the presence of “double“ or “triple“ therapy.
Subsequently AstraZeneca purchased the global commercial rights to
roflumilast from Takeda.
Dr Ken Cunningham, who also
joined the Board in September, was the CEO of Arakis, a respiratory
company sold to Sosei. He was also a former CEO of Skyepharma plc,
which developed the orally inhaled drug flutiform®, which is
approved in Europe and
Japan for the treatment of asthma
and licensed to Mundipharma. Ken was also chairman of Prosonix, an
inhalation development company, purchased by Circassia in 2015.
By adding Dr Ullman and Dr Cunningham to the Board we have
significantly expanded the expertise on the Board both in terms of
respiratory medicine and significant transaction experience.
References
1 Results were reported in a press release,
15 March 2016 (post period end)
2 IMS Consulting Group market research 2014
For further information, please
contact:
Verona Pharma plc |
Tel: +44 (0) 20 7863
3300 |
Jan-Anders Karlsson, CEO |
|
N+1 Singer |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / Jen
Boorer |
|
FTI Consulting |
Tel: +44 (0)20 3727 1000 |
Simon Conway / Julia Phillips |
|
About Verona Pharma plc
Verona Pharma plc is a UK-based clinical stage biopharmaceutical
company focused on the development of innovative prescription
medicines to treat respiratory diseases with significant unmet
medical needs, such as chronic obstructive pulmonary disease
(COPD), asthma and cystic fibrosis.
Verona Pharma's lead drug, RPL554, is a first-in-class drug
currently in Phase 2 trials as a nebulised treatment for acute
exacerbations of COPD in the hospital setting. The drug is a
dual phosphodiesterase (PDE) 3/4 inhibitor and therefore has both
bronchodilator and anti-inflammatory effects, which are essential
to the improvement of patients with COPD and asthma.
Verona Pharma is also building a broader portfolio of
RPL554-containing products to maximise its benefit to patients and
its value. This includes the very significant markets for
COPD and asthma maintenance therapy. In addition, the Company
is exploring the potential of the drug in different diseases, such
as cystic fibrosis, where it is in pre-clinical testing and has
received a Venture and Innovation Award from the UK Cystic Fibrosis
Trust.